Abstract 315P
Background
Cetuximab (an inhibitor of EGFR) is commonly utilized for the treatment of head and neck cancers. It has been employed in combination with radiation or multi-agent chemotherapy for locoregionally advanced and metastatic head and neck cancer respectively. This study explored the use of cetuximab plus an JAK1 inhibitor (JAK1i), which is a protein that is downstream in EGFR signaling, in order to test whether this dual inhibition could accentuate the effects of cetuximab.
Methods
Human head and neck squamous cell cancer cells (UM-SCC-6 cells) were cultured as previously described (Bonner JA et al., BMC Cancer 15:673). The JAK1 inhibitor (JAK1i) was obtained from Calbiochem, LaJolla, CA. Standard assays of immunoblots, proliferation, apoptosis and comet assays were utilized (Bonner JA et al., BMC Cancer 15:673).
Results
The combination of cetuximab (0.5 μg/ml) and JAK1i (1µM) resulted in greater inhibition of STAT-3 than either agent alone on immunoblot analysis. Likewise, the combination treatment resulted in greater inhibition of cell proliferation (at 72 hours), greater apoptosis and enhanced DNA double strand breaks (comet) compared to either agent given alone.
Conclusions
Cetuximab initially showed activity in head and neck cancer over 20 years ago. It is currently used in combination with radiation or chemotherapy for these patients. The results reported herein suggest that the anti-proliferative effects of cetuximab can be enhanced with the addition of JAK1 inhibition. Further work exploring the targeting of various steps in EGFR signaling is warranted in head and neck cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
James A. Bonner.
Funding
Has not received any funding.
Disclosure
J.A. Bonner: Honoraria (institution), Advisory / Consultancy: Bristol-Myers Squibb Company; Honoraria (institution), Advisory / Consultancy: Eli Lily and Company; Honoraria (institution), Advisory / Consultancy: Merck Serono; Honoraria (institution), Advisory / Consultancy: Cel-Sci. E. Yang: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Eli Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
448P - Incidence and severity of chemotherapy induced peripheral neuropathy in geriatric population who are receiving chemotherapy
Presenter: Alekhya Mandepudi
Session: Poster display session
Resources:
Abstract
449P - Utility of screening tool for assessment of chemotherapy induced peripheral neuropathy in cancer patients
Presenter: PRUTHVI Paibhavi
Session: Poster display session
Resources:
Abstract
450P - Supportive care to control nausea and dizziness in malignant tumours: A systematic review
Presenter: Rainer Spiegel
Session: Poster display session
Resources:
Abstract
451P - The safety of ramucirumab without H1-antihistamines as a premedication in patients with solid cancers: A retrospective study
Presenter: Nobuhiro Hattori
Session: Poster display session
Resources:
Abstract
452P - Expression of erythropoietin receptor in patient with anemia related chemotherapy and its correlation with absolute reticulocyte count
Presenter: Irza Wahid
Session: Poster display session
Resources:
Abstract
453P - Body mass index did not correlate with short term overall survival in breast cancers
Presenter: Jungsun Lee
Session: Poster display session
Resources:
Abstract
454P - Predictors of severity and comparison of CTCAE V3.0 vs V4.3 in assessing chemotherapy induced extravasation injuries
Presenter: Sangana Reddy
Session: Poster display session
Resources:
Abstract
455P - Assessment of nutritional status and quality of life among cancer patients undergoing chemotherapy
Presenter: Sri Prathima
Session: Poster display session
Resources:
Abstract
456P - Use of gamma irradiated bone allografts in treatment of various bone tumours
Presenter: Anchal Mishra
Session: Poster display session
Resources:
Abstract
457P - The prevalence of vitamin D deficiency in Thai cancer patients, its dynamics and association with cancer survival
Presenter: Chavapon Ngokngarm
Session: Poster display session
Resources:
Abstract